Literature DB >> 15772697

Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.

M Engelhardt, A M S Müller, W Maier, R Wäsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15772697     DOI： 10.1038/sj.leu.2403723

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.

Authors:  Fabrice Giraudet; Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-31       Impact factor: 2.503

2.  Chemotherapy-Induced Peripheral Neuropathy and its Impact on Health-Related Quality of Life among Multiple Myeloma Patients: A Single-Center Experience.

Authors:  Naila A Shaheen; Maha Alqahtani; Nada S Alawbthani; Abin Thomas; Ahmed Alaskar
Journal:  Indian J Palliat Care       Date:  2020-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.